SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...

Pittsburgh Public Theater is continuing to champion arts education and workforce development with a robust slate of programs ...

The holiday season brings joy, relief and celebration — and commerce — followed sometimes by a lull in economic activity and ...

Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study ...

Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and ...

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative ...

"This patent expands the applications for our targeted approach to treating cancer," said Dr. Mauro Ferrari, President and CEO of BrYet US, Inc. "It strengthens our ability to pair our delivery ...